Partnering Strategy and OpportunitiesPhylogica offers access to its Phylomer® drug discovery platform through contract discovery partnerships with pharmaceutical and biotechnology companies that are seeking novel peptide based therapeutic candidates against disease protein targets (intracellular or extracelluar) of interest. Phylogica’s partnership deals are structured on the basis of a technology access fee with associated payments on delivery of agreed milestones and royalties. IP advantage The peptide sequence derived from the Phylomer® platform rarely correspond to patented matter, expanding our partners’ freedom-to-operate against high value targets. |
|
 |